Table 3.
Univariable and multivariable analysis of the associations between potential factors with guidelines noncompliance (n = 280).
| Compliant with Guideline | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| Factors | Compliant, Number of Prescriptions (%) | Non-Compliant, Number of Prescriptions (%) |
Crude Odd Ratio for Non-Compliant (95% Confidence Interval) | p-Value | Adjusted Odd Ratio for Non-Compliant (95% Confidence Interval) | p-Value |
| Specialities | 0.231 | |||||
| Medical | 105 (60.3) | 69 (39.7) | 1.00 (Reference) | <0.001 b | 1.00 (Reference) | |
| Surgical | 21 (40.4) | 31 (59.6) | 2.25 (1.19–4.23) |
1.18 (0.57–2.46) |
0.661 | |
| ICU | 3 (50.0) | 3 (50.0) | 1.52 (0.30–7.76) |
0.85 (0.15–4.77) |
0.856 | |
| Oncology | 5 (35.7) | 9 (64.3) | 2.74 (0.88–8.52) |
1.72 (0.51–5.75) |
0.379 | |
| O&G | 1 (10.0) | 9 (90.0) | 13.70 (1.70–110.53) |
9.54 (1.10–82.89) |
0.041 | |
| Orthopaedic | 6 (25.0) | 18 (75.0) | 4.57 (1.73–12.07) |
2.26 (0.80–6.39) |
0.123 | |
| Route | 0.001 | |||||
| Oral | 73 (80.2) | 18 (19.8) | 1.00 (Reference) | <0.001 a | 1.00 (Reference) | |
| Intravenous | 64 (37.2) | 108 (62.8) | 6.84 (3.75–12.49) |
2.22 (0.93–5.31) |
0.072 | |
| Other * | 4 (23.5) | 13 (76.5) | 13.18 (3.84–45.26) |
19.05 (4.19–86.60) |
<0.001 | |
| Antimicrobial class | 0.149 | |||||
| Penicillin | 41 (39.0) | 64 (61.0) | 1.00 (Reference) | <0.001 b | 1.00 (Reference) | |
| Cephalosporin | 12 (22.2) | 42 (77.8) | 2.24 (1.06–4.76) |
2.18 (0.94–5.06) |
0.071 | |
| Quinolone | 7 (50.0) | 7 (50.0) | 0.64 (0.21–1.96) |
1.42 (0.28–7.620 |
0.673 | |
| Other ** | 29 (59.2) | 20 (40.8) | 0.44 (0.22–0.88) |
0.63 (0.25–1.60) |
0.334 | |
| Antifungal | 13 (68.4) | 6 (31.6) | 0.30 (0.10–0.84) |
1.05 (0.25–4.37) |
0.947 | |
| Antiviral ^ | 25 (100.0) | 0 (0.0) | 0 | NA | NA | |
| Antituberculosis ^ | 14 (100.0) | 0 (0.0) | 0 | NA | NA | |
| Number of prescriptions per patient | 0.001 | |||||
| 1 | 49 (39.5) | 75 (60.5) | 1.00 (Reference) | <0.001 a | 1.00 (Reference) | |
| 2 | 33 (45.2) | 40 (54.8) | 0.79 (0.44–1.42) |
0.99 (0.44–2.24) |
0.975 | |
| ≥3 | 59 (71.1) | 24 (28.9) | 0.27 (0.15–0.48) |
0.21 (0.08–0.53) |
0.001 | |
a Chi-Squared test; b Fisher-Exact test, * Other routes include topical, intraperitoneal. Each of these route types accounted for <5% of prescriptions. ** Other classes include macrolide, carbapenem, imidazole. Each comprising < 5% of prescriptions. ^ Disregard due to the small number of cases.